Join Growin Stock Community!

Denali therapeutics inc.DNLI.US Overview

US StockHealthcare
(No presentation for DNLI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

DNLI AI Insights

DNLI Overall Performance

DNLI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

DNLI Recent Performance

-0.59%

Denali therapeutics inc.

0.05%

Avg of Sector

-0.31%

S&P500

DNLI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

DNLI Key Information

DNLI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

DNLI Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Price of DNLI

DNLI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

DNLI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.28
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3643.65
PB Ratio
3.61
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.28
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3643.65
PB Ratio
3.61
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is DNLI's latest earnings report released?

    The most recent financial report for Denali therapeutics inc. (DNLI) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DNLI's short-term business performance and financial health. For the latest updates on DNLI's earnings releases, visit this page regularly.

  • How much cash does DNLI have?

    At the end of the period, Denali therapeutics inc. (DNLI) held Total Cash and Cash Equivalents of 205.33M, accounting for 0.18 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is DNLI's EPS continuing to grow?

    According to the past four quarterly reports, Denali therapeutics inc. (DNLI)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.73. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of DNLI?

    Denali therapeutics inc. (DNLI)'s Free Cash Flow (FCF) for the period is -100.06M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 12.67% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of DNLI?

    The latest valuation data shows Denali therapeutics inc. (DNLI) has a Price-To-Earnings (PE) ratio of -6.63 and a Price/Earnings-To-Growth (PEG) ratio of 4.17. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.